Next 10 |
home / stock / wuxif / wuxif news
2024-05-29 12:00:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 11:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 09:05:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 07:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 05:20:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-12 03:45:00 ET Summary Hangzhou Sciwind Biosciences out-licenses South Korean rights for ecnoglutide injection to HK inno.N Corporation for up to $56 million. Beijing's Sino Biological completes its $48 million acquisition of SignalChem Biotech, adding enzyme production ex...
2024-04-24 11:50:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. Top relative contributors in Q1 included Taiwan Semiconductor Manufacturing Company, ...
2024-03-31 04:50:00 ET Summary South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770M. AnHeart Therapeutics, a New York-Hangzhou biopharma, will become part of Nuvation Bio (NYSE: NUVB) of New Yo...
2024-03-30 00:10:00 ET Summary I wrote recently about the politically fraught state of the relations of biopharma companies with Chinese outsourcing companies, of which WuXi is probably the most prominent. There are bills in the works in both the House (the BIOSECURE Act) and the ...
2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...